



Investment objective

The DSC Equity Fund investment process identifies defensive, high-quality stocks and combines them with a risk-controlled portfolio. The aim of this two-stage process of equity screening and volatility minimization is to achieve a market-like return in times of rising markets and an excess return in phases of declining markets. Currency risks are partially hedged. This fund invests primarily in equities of the healthcare sector and related industries.

End of Accounting Period	04/30
Distribution date as of	07/01
Front-end load max.	3.00%
Management company	Gutmann KAG
Investment advisor	Dreyfus Banquiers
Marketing authorisation	CH
AuM in CHF	48,854,559.82
Tradeability	Austrian bank working days*

*except Good Friday, New Year's Eve

Risk indicator according to the Key Information Document ("PRIIPs KID")

Lower risk Higher risk

1 2 3 4 5 6 7

Further information on the fund's Summary Risk indicator ("SRI") can be found in the Key Information Document ("PRIIPs KID"). A comprehensive explanation of the risks is provided in the prospectus under the item "Risk profile of the fund".

Top security holdings

Novo-Nordisk AS	5.46%
Eli Lilly and Company	5.43%
JOHNSON & JOHNSON	5.00%
Xtr.(IE)-MSCI Wrld Health Care	4.96%
Merck & Co. Inc.	4.48%
UNITEDHEALTH GROUP INC.	4.23%
ABBOTT LABORATORIES	3.49%
REGENERON PHARMACEUTICALS INC.	3.31%
AbbVie Inc.	2.96%
AMGEN INC.	2.65%

DSC Equity Fund - Healthcare


ISIN: AT0000A1FNT0

A distributing fund according to Austrian law

Net asset value (AA) CHF 242.85

March 2024

Sector analysis



Performance 5 years (in CHF)



Performance figures

	total	p.a.**
Inception (11/2015 - 03/2024)	43.25%	4.37%
5 years (04/2019 - 03/2024)	21.47%	3.97%
3 years (03/2021 - 03/2024)	7.77%	2.53%
1 year (03/2023 - 03/2024)	11.26%	11.26%
Beginning of year (12/2023 - 03/2024)	15.72%	

** yearly average

Investing in funds is subject to market risks. Historical performance is not a guide to current or future performance. The performance data do not take into account any costs or commissions incurred when issuing or redeeming units. The performance is calculated in line with the provisions of the Asset Management Association Switzerland. This factsheet is for information and marketing purposes. The relevant documents (prospectus, PRIIPs KID) as well as the latest annual and semi-annual reports may be obtained free of charge from the representative and paying agent in Switzerland, Dreyfus Sons & Co Ltd, Banquiers, Aeschenvorstadt 16, 4051 Basel.